Neurocrine Biosciences (NBIX) opened 2026 with Q1 revenue of US$814.5 million and basic EPS of US$1.97, while trailing 12 month figures sit at US$3.1 billion of revenue and EPS of US$6.71, setting a firm earnings-season backdrop. The company has seen quarterly revenue move from US$572.6 million in Q1 2025 to US$814.5 million in Q1 2026, with basic EPS shifting from US$0.08 to US$1.97 over the same period. Earnings growth of 118.6% over the past year and forecast EPS growth of about 21.1% per year keep the focus squarely on how durable the current margin profile really is.

See our full analysis for Neurocrine Biosciences.

With the headline numbers on the table, the next step is to see how they line up against the widely followed narratives around growth, risks, and earnings quality that investors have been using to frame Neurocrine Biosciences's story.

EPS Momentum Outpaces Revenue Trend

• On a trailing basis, EPS sits at US$6.71 while total revenue is US$3.1b, compared with Q1 2026 quarterly figures of US$1.97 EPS and US$814.5 million of revenue, which shows earnings growing faster than the top line in the recent period.
• Consensus narrative points to leadership in neurology products and an expanding market, and the current numbers partly echo that, but also show where expectations need a sanity check.
  • Earnings rose 118.6% over the last year while revenue is forecast at about 11.1% annual growth, so profits are moving much faster than sales in the recent data, which is stronger than a simple “steady growth” story.
  • Analysts also talk about profit margins rising toward the mid 20s, and the reported trailing net margin of 21.6% versus 12.7% a year earlier already lines up with that view, although future margins will still depend on how product mix and pricing develop.

Margins And Profit Quality Under The Microscope

• Net income in Q1 2026 is US$197.9 million on US$814.5 million of revenue, which is consistent with the trailing 12 month net profit of US$668.6 million on US$3.1b of revenue that corresponds to the 21.6% margin flagged in the analysis.
• Bulls argue that expanding access for key drugs and a broader late stage pipeline can support higher margins over time, and the current earnings profile gives that view some concrete backing but also sets a high bar.
  • For example, bullish assumptions talk about margins rising from 12.7% to 25.6%, and the move to a 21.6% trailing margin already covers a large part of that gap on the numbers provided.
  • At the same time, those bullish expectations sit alongside forecasts for revenue growth of 18.9% in the optimistic case versus 11.1% in the base forecasts, so the present margin strength will need to hold up if those higher growth paths are to remain credible.

On the bullish side, some investors see these margins as evidence that the product portfolio can support higher long term earnings, and they lay out that view in more detail in the 🐂 Neurocrine Biosciences Bull Case.

Valuation Signals Versus Bearish Concerns

• With the stock at US$147.02, the data set points to a DCF fair value of about US$513.16 and an analyst price target of about US$189.73, while the current P/E of 22.1x is slightly below peers at 23.2x but above the US biotech industry average of 17.6x.
• Bears focus on reliance on a few flagship products and sector pricing pressure, and the valuation metrics cut both ways when you line them up against that cautious view.
  • On one hand, the gap between the share price and the US$189.73 analyst target and the much higher DCF fair value estimate suggests the current price already bakes in some of the risks around growth and margins that skeptics highlight.
  • On the other hand, the P/E premium to the broader biotech industry at 22.1x versus 17.6x fits the bearish concern that investors are still paying up for the current growth and margin profile, which could matter if future revenue growth comes in closer to the 9.7% bearish revenue scenario.

Skeptical investors often stress those concentration and pricing risks, and you can see how they build that case around the current numbers in the 🐻 Neurocrine Biosciences Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Neurocrine Biosciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of optimism and caution feels familiar, that is the point: the data clearly supports more than one story. Act quickly by checking how the current rewards stack up for your thesis in the 4 key rewards

See What Else Is Out There

For all the strong margins and EPS, the stock still trades at a P/E premium to the wider biotech industry and below both DCF and analyst value markers.

If that mismatch between price and perceived value makes you cautious, compare this setup with companies flagged in the 45 high quality undervalued stocks to see whether any align better with your return goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.